NSC vs TGTX · P/E 18, rev $6.46B vs P/E 18, rev $240.3M
Norfolk Southern Corporation (NSC) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported NSC revenue for 2026-06-30 was $6.46B. Net income was $1.28B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
NSC currently screens at market cap $60.10B and trailing P/E 18.2. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the NSC and TGTX stock pages for the full models.
Not investment advice.